Janssen Pharmaceuticals, Inc.
Recent News About Janssen Pharmaceuticals, Inc. View More
-
-
At first-of-its-kind trial in Philadelphia, J&J says there were no 'spin' tactics with Risperdal
PHILADELPHIA – In continuing testimony taken during the first punitive damages trial surrounding anti-psychotic drug Risperdal in Philadelphia, a Johnson & Johnson senior director said that the company and its subsidiary Janssen Pharmaceuticals were not responsible for attempting to “spin” information provided to the media about the medication.
-
J&J senior director says Risperdal targeting to child doctors wasn't off-label promotion
PHILADELPHIA – Johnson & Johnson did not market anti-psychotic drug Risperdal off-label to pediatricians and pediatric psychologists prior to receiving Food & Drug Administration approval, according to a senior official testifying in a trial meant to determine if the pharmaceutical giant will be penalized with punitive damages.
-
Ex-FDA commissioner says Risperdal was promoted for kids before it was approved; J&J maintains it was safe
PHILADELPHIA – Testimony in the Risperdal punitive damages trial continued Thursday with a former Food & Drug Administration commissioner who said Johnson & Johnson and its subsidiary Janssen Pharmaceuticals sought to promote use of Risperdal in children and adolescents, before it was given such approval – but the company maintains it was safe for that age group.
-
Philadelphia judge denies J&J's attempt to avoid upcoming Risperdal punitive damages trial
PHILADELPHIA – A state court judge decided that a new punitive damages trial will proceed in a Risperdal action that initially resulted in a $1 million-plus verdict in 2015 – above Johnson & Johnson’s attempt to dismiss the case through a motion for summary judgment.
-
-
-
Janssen win in Philly Risperdal case overturned by appeals court
HARRISBURG – The Superior Court of Pennsylvania has reinstated a Risperdal lawsuit which was thrown out after 11 days of trial proceedings in a Philadelphia court in December 2016 and said its original granting of nonsuit was improper.
-
Houston men sue in Philly as J&J faces more claims from Invokana users who say they were at higher risk for amputations
PHILADELPHIA – More lawsuits are alleging that Johnson & Johnson’s diabetes medication, Invokana, gave them an increased risk of suffering amputations – and that the company failed to warn them of that same risk.
-
Three more plaintiffs allege Invokana makers failed to warn them of increased risk for amputations
PHILADELPHIA – A trio of new lawsuits joins others recently filed taking aim at Johnson & Johnson’s Invokana medication for Type 2 diabetes, claiming the company failed to warn its users that the medicine put them at increased risk for amputations they suffered as a result of taking the drug.
-
'Verdilization': It's how a baby lawsuit is made
All it takes is one maturing into a headline-grabbing, multimillion-dollar verdict to spawn thousands more like it.
-
Delco couple's lawsuit claims taking Invokana for diabetes caused plaintiff to suffer amputations
PHILADELPHIA – A Delaware County couple have launched legal action against Johnson & Johnson and its subsidiary Janssen Pharmaceuticals, claiming its Type 2 diabetes treatment medication Invokana failed to contain warnings regarding users being at increased risk for amputations.
-
'A tipping point:' Punitive damages question to be decided in pair of Philadelphia Risperdal cases
PHILADELPHIA – A Philadelphia judge’s decree has paved the way for new trials in two Risperdal cases, in order to determine the applicability of punitive damages in those same actions.
-
Johnson & Johnson, Bayer seek dismissal of 12 Philadelphia Xarelto lawsuits, say fact sheets are missing
PHILADELPHIA – According to a recent filing, counsel for the manufacturers of blood thinner-drug Xarelto are looking to have the lawsuits of certain plaintiffs dismissed with prejudice, supposedly for not complying with filing guidelines.
-
In Philadelphia, only 16% of new pharma cases are from Pennsylvania residents
PHILADELPHIA – A notable 2017 U.S. Supreme Court decision intended to limit the practice of forum-shopping has not deterred thousands of plaintiffs from filing pharmaceutical litigation in Philadelphia courts, recently-released statistics show.
-
Unbeaten at trial, Bayer and Janssen say cycle of Xarelto lawsuits 'needs to be stopped'
Early returns haven't been positive for plaintiffs attorneys, so Xarelto liability theories have been mutating, defense says